Verrica Pharmaceuticals reported a 57.9% year-over-year increase in U.S. YCANTH product revenue to $5.7 million in Q3 2026, driven by strong sales and improved prescription conversion. The company completed enrollment in the first pivotal Phase 3 trial for common warts and expects topline data in early and mid-2027. Verrica also unlocked $27.5 million in non-dilutive growth capital, extending its cash runway through these trial readouts. Additionally, it is exploring the development of VP-315 for treating Gorlin syndrome, a rare genetic disease causing basal cell carcinomas.
Verrica Pharmaceuticals' Q3 2026 financial results provide context for health sector activity. For readers following health stocks, 23 of 150 Pluang-traded US health stocks rose while 124 fell. Notable movers include RXRX at USD 3.34 with a -6.96% change, HRTX at USD 0.33 with -6.90%, and TWST at USD 114.14 with -6.89%, as of Nov 13, 2026 04:11 WIB.
Super League Enterprise, a company specializing in audience intelligence and media activation for the gaming industry, announced it will release its financial results for the third quarter ending September 30, 2026, on November 16, 2026, after market...
Stantec Inc. reported a 9.4% increase in net revenue to $1.9 billion for Q3 2026, driven by organic and acquisition growth. Adjusted EBITDA rose 16.6% to $377.1 million with a record margin of 20.2%, while adjusted EPS grew 23.5% to $1.89. The compan...
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
